Physician
Germain, Sephora
Germain, Sephora was paid $159K by Medicaid between Dec 2018 and Jan 2023, across 12 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 47% of everything it billed.
33Billing provider infoGERMAIN, SEPHORA
WEST NYACK, NY 10994
WEST NYACK, NY 10994
33aNPI1831538149assigned 06/19/2013
33bProvider typePediatrics Physician
28Total paid$159K
24GClaims1,965
24DCodes billed12
24AFirst – last monthDec 2018 – Jan 2023
Compared with peers
Next to other Pediatrics Physician providers in New York
Rank by total paid#619 of 1,983
Median peer was paid$17K
This provider vs. median9.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13 | $235.70 | |
| 2019 | 97 | $2K | |
| 2020 | 163 | $10K | |
| 2021 | 669 | $62K | |
| 2022 | 943 | $76K | |
| 2023 | 80 | $9K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 47% | 690 | 662 | $74K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 23% | 257 | 242 | $37K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 19% | 215 | 213 | $30K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.3% | 523 | 512 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 29 | 29 | $2K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13 | 13 | $2K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 12 | 12 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 30 | 30 | $625.00 |
| 92551 | <1% | 12 | 12 | $145.85 | |
| 96127 | <1% | 13 | 13 | $81.32 | |
| 90686 | <1% | 158 | 158 | $36.74 | |
| 96160 | 0% | 13 | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.